| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo and Kaleida Health, Buffalo, New York 14209
Address all correspondence and requests for reprints to: Paresh Dandona, B.Sc., M.B. B.S., D.Phil., F.R.C.P., Director, Diabetes-Endocrinology Center of Western New York, Chief of Endocrinology, State University of New York at Buffalo, 3 Gates Circle, Buffalo, New York 14209. E-mail: pdandona{at}KaleidaHealth.org.
Type 2 diabetes is associated with lower total testosterone (T) levels in cross-sectional studies. However, it is not known whether the defect is primary or secondary. We investigated the prevalence of hypogonadism in type 2 diabetes by measuring serum total T, free T (FT), SHBG, LH, FSH, and prolactin (PRL) in 103 type 2 diabetes patients. FT was measured by equilibrium dialysis. FT was also calculated by using T and SHBG (cFT). Hypogonadism was defined as low FT or cFT. The mean age was 54.7 ± 1.1 yr, mean body mass index (BMI) was 33.4 ± 0.8 kg/m2, and mean HbA1c was 8.4 ± 0.2%. The mean T was 12.19 ± 0.50 nmol/liter (351.7 ± 14.4ng/dl), SHBG was 27.89 ± 1.65 nmol/liter, and FT was 0.250 ± 0.014 nmol/liter. Thirty-three percent of patients were hypogonadal. LH and FSH levels were significantly lower in the hypogonadal group compared with patients with normal FT levels (3.15 ± 0.26 vs. 3.91 ± 0.24 mIU/ml for LH and 4.25 ± 0.45 vs. 5.53 ± 0.40 mIU/ml for FSH; P < 0.05). There was a significant inverse correlation of BMI with FT (r = –0.382; P < 0.01) and T (r = –0.327; P < 0.01). SHBG correlated inversely with BMI (r = –0.267; P < 0.05) but positively with age (r = 0.538; P < 0.001) and T (r = 0.574; P < 0.001). FT correlated strongly with cFT (r = 0.919; P < 0.001) but not with SHBG. LH levels correlated positively with FT (r = 0.287; P < 0.05). We conclude that hypogonadotropic hypogonadism occurs commonly in type 2 diabetes.
This article has been cited by other articles:
 |
|
 |
|
  F Ermetici, F Donadio, L Iorio, A E Malavazos, A Dolci, E Peverelli, A M Barbieri, L Morricone, I Chiodini, M Arosio, et al. Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on Leydig cell function Eur. J. Endocrinol., December 1, 2009; 161(6): 853 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. I Hackett Review: Androgens, erectile dysfunction and cardiovascular risk in type 2 diabetes The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 214 - 217. [Abstract] [PDF]
|
|
|
|
|
|
G. I Hackett, N. S Cole, A. A Deshpande, M. D Popple, D. Kennedy, and P. Wilkinson Biochemical hypogonadism in men with type 2 diabetes in primary care practice The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 226 - 231. [Abstract] [PDF]
|
|
|
|
 |
|
 Q. Xu, A. Prabhu, S. Xu, M. B. Manigrasso, and C. Maric Dose-dependent effects of dihydrotestosterone in the streptozotocin-induced diabetic rat kidney Am J Physiol Renal Physiol, August 1, 2009; 297(2): F307 - F315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Theodoraki and P.-M. Bouloux Testosterone therapy in men Menopause Int, June 1, 2009; 15(2): 87 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Traish, F. Saad, and A. Guay The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance J Androl, January 1, 2009; 30(1): 23 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Yassin and F. Saad Testosterone and Erectile Dysfunction J Androl, November 1, 2008; 29(6): 593 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rice, R. E. Brannigan, R. K. Campbell, S. Fine, L. Jack Jr, J. B. Nelson, and J. Regan-Klich Men's Health, Low Testosterone, and Diabetes: Individualized Treatment and a Multidisciplinary Approach The Diabetes Educator, November 1, 2008; 34(5_suppl): 97S - 112S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chandel, S. Dhindsa, S. Topiwala, A. Chaudhuri, and P. Dandona Testosterone Concentration in Young Patients With Diabetes Diabetes Care, October 1, 2008; 31(10): 2013 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Farrell, A. Deshmukh, and A. A. Baghaie Low Testosterone and the Association With Type 2 Diabetes The Diabetes Educator, September 1, 2008; 34(5): 799 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kapoor, K. S Channer, and T H. Jones Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes Diabetes and Vascular Disease Research, June 1, 2008; 5(2): 135 - 137. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Grossmann, M. C. Thomas, S. Panagiotopoulos, K. Sharpe, R. J. MacIsaac, S. Clarke, J. D. Zajac, and G. Jerums Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1834 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Kasturi, J. Tannir, and R. E. Brannigan The Metabolic Syndrome and Male Infertility J Androl, May 1, 2008; 29(3): 251 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dhindsa, V. Bhatia, G. Dhindsa, A. Chaudhuri, G. M. Gollapudi, and P. Dandona The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients Diabetes Care, July 1, 2007; 30(7): 1860 - 1861. [Full Text] [PDF]
|
|
|
|
|
|
D Kapoor, S Clarke, R Stanworth, K S Channer, and T H Jones The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes Eur. J. Endocrinol., May 1, 2007; 156(5): 595 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kapoor, H. Aldred, S. Clark, K. S. Channer, and T. H. Jones Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity Diabetes Care, April 1, 2007; 30(4): 911 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bhatia, A. Chaudhuri, R. Tomar, S. Dhindsa, H. Ghanim, and P. Dandona Low Testosterone and High C-Reactive Protein Concentrations Predict Low Hematocrit in Type 2 Diabetes Diabetes Care, October 1, 2006; 29(10): 2289 - 2294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Hammoud, M. Gibson, C. M. Peterson, B. D. Hamilton, and D. T. Carrell Obesity and Male Reproductive Potential J Androl, September 1, 2006; 27(5): 619 - 626. [Full Text] [PDF]
|
|
|
|
 |
|
 W. de Ronde, Y. T. van der Schouw, H. A.P. Pols, L. J.G. Gooren, M. Muller, D. E. Grobbee, and F. H. de Jong Calculation of Bioavailable and Free Testosterone in Men: A Comparison of 5 Published Algorithms Clin. Chem., September 1, 2006; 52(9): 1777 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Kapoor, E Goodwin, K S Channer, and T H Jones Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol., June 1, 2006; 154(6): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tomar, S. Dhindsa, A. Chaudhuri, P. Mohanty, R. Garg, and P. Dandona Contrasting Testosterone Concentrations in Type 1 and Type 2 Diabetes Diabetes Care, May 1, 2006; 29(5): 1120 - 1122. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Goldfarb Low Testosterone Should Arouse Clinical Interest DOC News, December 1, 2005; 2(12): 1 - 8. [Full Text]
|
|
|
|
|
|
A. Morton Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1903 - 1903. [Full Text] [PDF]
|
|
|
|
|
|
S. Dhindsa, S. Prabhakar, and P. Dandona Authors' Response: Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1903 - 1903. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
